Lori Wood

11.0k total citations · 2 hit papers
202 papers, 4.8k citations indexed

About

Lori Wood is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Lori Wood has authored 202 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Pulmonary and Respiratory Medicine, 77 papers in Molecular Biology and 72 papers in Cancer Research. Recurrent topics in Lori Wood's work include Renal cell carcinoma treatment (138 papers), Cancer Genomics and Diagnostics (68 papers) and Renal and related cancers (65 papers). Lori Wood is often cited by papers focused on Renal cell carcinoma treatment (138 papers), Cancer Genomics and Diagnostics (68 papers) and Renal and related cancers (65 papers). Lori Wood collaborates with scholars based in Canada, United States and Denmark. Lori Wood's co-authors include Toni K. Choueiri, Georg A. Bjarnason, Frede Donskov, Brian I. Rini, Daniel Y.C. Heng, Christian Kollmannsberger, Ulka N. Vaishampayan, Sun Young Rha, Neeraj Agarwal and Mary J. MacKenzie and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Lori Wood

187 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

2013 730 citations Daniel Y.C. Heng, Wanling Xie et al. profile →
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

2018 306 citations Michael A.S. Jewett, Lori Wood et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lori Wood Canada	32	3.6k	2.4k	1.6k	1.6k	1.1k	202	4.8k
Lauren C. Harshman United States	32	2.8k 0.8×	1.4k 0.6×	1.8k 1.1×	1.2k 0.7×	1.2k 1.1×	194	4.3k
Jennifer Bacik United States	30	5.0k 1.4×	3.8k 1.6×	2.1k 1.3×	2.3k 1.4×	2.2k 2.0×	43	7.4k
D. Scott Ernst Canada	30	2.8k 0.8×	1.2k 0.5×	1.8k 1.1×	767 0.5×	925 0.8×	77	4.3k
Frédéric Pouliot Canada	31	2.8k 0.8×	1.8k 0.8×	1.4k 0.9×	1.1k 0.7×	647 0.6×	196	4.5k
David Y.T. Chen United States	38	3.6k 1.0×	3.1k 1.3×	808 0.5×	1.0k 0.7×	1.4k 1.3×	134	5.3k
Jean‐Jacques Patard France	33	2.9k 0.8×	2.2k 0.9×	579 0.4×	1.0k 0.7×	938 0.8×	47	3.6k
Pablo Maroto Spain	27	1.8k 0.5×	1.3k 0.5×	1.5k 1.0×	763 0.5×	1.7k 1.5×	164	3.9k
Mehmet Asım Bilen United States	34	1.5k 0.4×	921 0.4×	2.1k 1.3×	572 0.4×	1.1k 1.0×	317	4.1k
Jacques Tostain France	34	3.3k 0.9×	2.5k 1.1×	667 0.4×	1.1k 0.7×	1.2k 1.1×	72	4.1k
Eli Rosenbaum Israel	34	972 0.3×	1.7k 0.7×	1.0k 0.6×	655 0.4×	615 0.6×	112	3.6k

Countries citing papers authored by Lori Wood

Since Specialization

Citations

This map shows the geographic impact of Lori Wood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Wood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Wood more than expected).

Fields of papers citing papers by Lori Wood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Wood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Wood. The network helps show where Lori Wood may publish in the future.

Co-authorship network of co-authors of Lori Wood

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Wood. A scholar is included among the top collaborators of Lori Wood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Wood. Lori Wood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghosh, Sunita, Lori Wood, C. Kollmannsberger, et al.. (2025). Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients. Cancers. 17(3). 522–522. 2 indexed citations

Hamilou, Zineb, Sunita Ghosh, Daniel Yick Chin Heng, et al.. (2025). Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma. The Oncologist. 30(9). 1 indexed citations

Tanguay, Simon, Lori Wood, C. Kollmannsberger, et al.. (2025). Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study. Clinical Genitourinary Cancer. 23(3). 102342–102342. 1 indexed citations

Rendon, Ricardo, et al.. (2024). An in-depth analysis on the effects of body composition in patients receiving neoadjuvant chemotherapy for urothelial cell carcinoma. Canadian Urological Association Journal. 18(6). 180–184. 3 indexed citations

Saad, Eddy, Georges Gebrael, Renée Maria Saliby, et al.. (2024). Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens. The Oncologist. 29(8). 699–706.

Graham, Jeffrey, Sunita Ghosh, Rodney H. Breau, et al.. (2024). Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis). Clinical Genitourinary Cancer. 22(3). 102060–102060.

Ghosh, Sunita, Lori Wood, Georg A. Bjarnason, et al.. (2024). Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database. Current Oncology. 31(8). 4704–4712. 3 indexed citations

Ghosh, Sunita, Antonio Finelli, Lori Wood, et al.. (2023). Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System. JCO Global Oncology. 9(9). e2300271–e2300271. 1 indexed citations

Takemura, Kosuke, J. Connor Wells, Camillo Porta, et al.. (2023). Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology. 41(16_suppl). 4538–4538. 2 indexed citations

10.

Takemura, Kosuke, Naveen S. Basappa, Bernadett Szabados, et al.. (2023). Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology. 41(6_suppl). 600–600. 2 indexed citations

11.

Graham, Jeffrey, J. Connor Wells, Shaan Dudani, et al.. (2022). Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer. 171. 124–132. 20 indexed citations

12.

Wood, Lori, Robert J. Hamilton, Piotr Czaykowski, et al.. (2022). Testicular cancer survivorship: Long-term toxicity and management. Canadian Urological Association Journal. 16(8). 257–272. 12 indexed citations

13.

Gan, Chun Loo, Igor Stukalin, Daniel E. Meyers, et al.. (2021). Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer. 151. 115–125. 32 indexed citations

14.

Kushnir, Igal, Naveen S. Basappa, Sunita Ghosh, et al.. (2021). Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer. 19(6). 521–530. 12 indexed citations

15.

Rini, Brian I., Michael B. Atkins, Elizabeth R. Plimack, et al.. (2021). Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. European Urology Oncology. 5(2). 225–234. 25 indexed citations

16.

Chen, Gan, Daniel E. Meyers, Igor Stukalin, et al.. (2020). 425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology. 31. S1408–S1408. 2 indexed citations

17.

Graham, Jeffrey, J. Connor Wells, Frede Donskov, et al.. (2019). Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology. 2(6). 643–648. 31 indexed citations

18.

Haas, Naomi B., Judith Manola, Bonnie Ky, et al.. (2015). Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805. Clinical Cancer Research. 21(18). 4048–4054. 46 indexed citations

19.

Oechsle, Karin, Friedemann Honecker, Tina Cheng, et al.. (2011). Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Annals of Oncology. 22(12). 2654–2660. 72 indexed citations

20.

Wood, Lori. (1984). "Public Policy" Discrimination in the EEC: A Proposal for Assuring the Free Movement of Workers. Fordham international law journal. 8(3). 447.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact